Latest news with #Cellular
Jordan News
6 days ago
- Entertainment
- Jordan News
"One Of The Year's Best Thrillers": Roger Ebert Was Really Impressed With Chris Evans' 2004 Action Movie - Jordan News
Chris Evans' 2004 Action Movie Long before Chris Evans became an icon in the MCU, he earned praise in an underrated thriller. While he had previous success in Hollywood, Evans' role as Captain America in the MCU launched him to another level of fame. He became one of the faces of the cinematic universe before retiring the character in Avengers: Endgame. اضافة اعلان Since then, Evans has been trying to take roles that move away from the stoic hero. His spoiled villain role in the cast of Knives Out and his recent rom-com success in The Materialists earned him strong reviews. However, there were some early roles that already gave hints of the kind of success Chris Evans' career would deliver. Coming off his memorable comedic turn in the spoof movie Not Another Teen Movie, Cellular provided a more serious role for Chris Evans. Evans starred as Ryan, a young man who gets a call from a kidnapped woman (Kim Basinger) looking for help, turning him into her unlikely hero. The thriller was a change of pace for the actor, and it ended up receiving mixed reviews, earning 56% on Rotten Tomatoes. However, earned especially high praise from legendary film critic Roger Ebert, who called it "one of the year's best thrillers." Ebert even pointed to Evans's performance as a "star-making" role (via Though not all reviews were as kind, the praise from Ebert goes a long way in legitimizing a thriller like this. Cellular was a decent box office success, earning $57 million on a budget of $25 million (via Box Office Mojo). The success was a career boost for Evans, being cast as Johnny Storm in Fantastic Four the following year. In Roger Ebert's review of Cellular, he highlighted that the movie has a gimmicky setup, but it works because it is intelligent in how it's used. The film kicks off the intrigue by putting Kim Basinger's kidnapped Jessica in a situation where she can only make one call and doesn't know who it is going to, randomly connecting with Ryan. Ryan is already established as a guy who is not one to step up at a crucial time, but he is also not willing to ignore this woman in need. Thus, this reluctant and underqualified hero is thrust into a situation in which he gradually proves himself to be capable of more than he and everyone else thought. It is a solid setup of characters and premise that impressively manages to keep it exciting and smart throughout. Each time it seems like there would be an easy solution for Ryan, a new complication arises that throws him further into trouble. Likewise, it is fun to see him having to problem-solve with each new obstacle. The cast supporting Evans is also solid, bringing interesting layers to the movie. Basinger is essential as the victim, but she gets moments to be a hero herself. Jason Statham gets a great villain to play, and William H. Macy has fun as a mild-mannered cop dragged into the mess. Suits actor Rick Hoffman also has a small scene-stealing is not a perfect movie, but it is a fast-paced thriller that delivers on its fun idea. It is also entertaining to see Chris Evans in a smaller film than fans are used to, yet still giving fans a great hero to root for.
Yahoo
14-06-2025
- Health
- Yahoo
Las Vegas hospital Nevada's first with 2 cutting-edge treatments
LAS VEGAS (KLAS) — MountainView Hospital is making history as the first hospital in Nevada to perform both CAR T-cell therapy and allogeneic stem cell transplants, two cutting-edge treatments that can be lifesaving for patients battling blood cancers and other serious disorders. CAR T-cell therapy involves turning a patient's own cells into powerful weapons against their disease, while allogeneic stem cell transplant uses healthy donor cells to aid in recovery. These highly complex and sophisticated therapies have become a crucial tool in extending and, in many cases, saving the lives of patients with hard-to-treat disorders. 'There are two therapies. One is allogeneic stem cell transplant, which allows us to provide stem cells from other donors to patients who have a need for that. We are also bringing CAR T therapy which uses the patient's own cells,' said Dr. Carolyn Mulroney, medical director of the Sarah Cannon transplant and the CAR T-cell therapy program. Usually, many patients and their families have been forced to travel out of state to access these advanced treatments, adding financial stress and uncertainty during a difficult time. Now, thanks to MountainView's Sarah Cannon Transplant & Cellular Therapy Program, these lifesaving options are available close to home, supported by a team of multidisciplinary experts. This significant breakthrough comes just ahead of the grand opening for MountainView's first-of-its-kind 12,000-square-foot Day Hospital, a state-of-the-art facility designed to provide convenient, patient-centric care under one roof. The new Day Hospital will enable patients to undergo extensive treatments while retaining their routines and staying connected with their support networks. 'In an outpatient setting like this, it allows the patient to go home at the end of the day, sleep in their own bed, and be with their family,' Maria Rios, administrative director at MountainView Hospital, said. This marks a major step forward in health care for Nevada, ensuring that patients battling some of the most aggressive blood disorders can find hope without having to leave their community. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
28-03-2025
- Business
- Yahoo
Why United States Cellular Corp (USM) Is Surging In 2025?
We recently published a list of . In this article, we are going to take a look at where United States Cellular Corporation (NYSE:USM) stands against other telecom stocks that are surging in 2025. The telecom sector has seen many ups and downs in the past few years. Post-COVID, these stocks declined even more due to the inflation wave and the subsequent interest rate hikes. Telecommunication companies usually have significant debt on their balance sheets due to infrastructure CapEx, and they were among the hardest hit. However, rates are now slowly coming down, and these stocks are also starting to bottom out and turn a corner. Many telecom stocks are still profitable and pay dividends. Falling bond yields are making them even more attractive. It's a good idea to keep tabs on which telecom stocks are spearheading the gains so far this year. For this article, I screened the best-performing telecom stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A technician working on a handset in a laboratory setting, highlighting the top-level technology used by the telecommunications company. Number of Hedge Fund Holders In Q4 2024: 19 United States Cellular Corporation (NYSE:USM) sells wireless telecom services. The stock is up significantly so far in 2025 as UScellular (NYSE:USM) entered into agreements with Verizon and AT&T to sell substantial portions of its spectrum assets. The Verizon deal involves $1 billion worth of AWS, Cellular, and PCS licenses, while the AT&T agreement includes $1.018 billion for 3.45 GHz and 700 MHz licenses. These transactions collectively represent approximately $2.02 billion in total consideration for about 70 percent of the company's spectrum holdings. Earlier, UScellular (NYSE:USM) announced an agreement to sell its wireless operations and 30 percent of its wireless spectrum licenses to T-Mobile. This transaction is expected to close in mid-2025. The consensus price target of $86.33 implies 26.12% upside. USM stock is up 9.23% year-to-date. Overall, USM ranks 13th on our list of telecom stocks that are surging in 2025. While we acknowledge the potential of USM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than USM but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
